Scientific advisory board

Leif G Salford

Chairman of the scientific advisory board

Leif G. Salford is one of the founders of Idogen, senior professor of neurosurgery and director of the Rausing laboratory for translational neurooncology at Lund University. His scientific work combines immune- and gene therapy for the most malignant brain tumors and he has also been widely recognized for his work on the effect of electromagnetic radiation on the blood-brain barrier. Professor Salford has conducted research in neurosurgery at Lund University, University of Gothenburg, Kuwait University and Cornell Medical Centre in New York. He has had several important assignments, such as chief medical officer at the Sahlgrenska hospital, divisional manager and board member of the Lund University Hospital board, head of the department of Clinical Sciences, Lund University and has been Chairman of the World federation of neurosurgical societies (WFNS) committee on neurooncology and President of the European association for neurooncology (EANO).

Hanne Risager Romedahl

CSO

Hanne Risager Romedahl has >10 years of experience from senior leadership positions within R&D in the pharmaceutical industry and most recently from a role as Senior Vice President at the German drug development company Evotec International GmbH. Before that Hanne worked for more than 9 years as Vice President in the research organization of Novo Nordisk A/S, where she was responsible for project innovation and portfolio management within hematological and immunological diseases, and has founded several new competency areas and departments. Before that, Hanne worked as leader within the biotech sector. Hanne holds a M.Sc. from the Royal Veterinary and Agricultural University, Copenhagen and a PhD/Post Doc in immunology from the Technical University of Denmark/Michigan State University, USA. Both academically as well as during her whole industrial career, Hanne has substantial research experience with dendritic cells as well as immunology in general.

Anette Sundstedt

Anette Sundstedt has over 15 years of experience in research and development in the pharmaceutical industry and comes most recently from a role as a senior researcher and project manager at Active Biotech AB. Anette has previously led a research group focusing on immunological tolerance at Lund University and conducted research in immunotherapy for autoimmune diseases at the University of Bristol, UK. Anette Sundstedt holds a M.Sc. in cellular and molecular biology and a Ph.D. in tumor immunology from Lund University.

Rolf Ljung

Rolf Ljung is professor of Paediatrics at Lund University and senior consultant in paediatric haematology with special focus coagulation at Skåne University Hospital. His research focuses on bleeding and coagulation disorders in children and in particular genetic and clinical studies in haemophilia. An important work has been to map the genetic variation of the diseases, for example to predict the risk for a person with hemophilia to develop antibodies against their treatment. Professor Ljung is also scientific chairman of the “European Paediatric Network for Haemophilia Management” (PedNet) and ”International Network on Pediatric Hemophilia” (INPH).

Hans-Olov Sjögren

Hans-Olov Sjögren is one of the founders of Idogen and professor emeritus in tumor immunology at Lund University. By research activities at Karolinska Institute in Stockholm, Fred Hutchinson Cancer center in Seattle and at Wallenberg laboratory and Biomedical Centre at Lund University he has contributed significantly to the understanding of the immune reactivity against cancer, both in experimental models and in patients. The research of professor Sjögren focuses on the mechanisms balancing immune activation and suppression in tumor disease and led to the discovery of a molecular tool to enhance an immune suppressive mechanism, the principle that Idogen builds on.

Richard Williams

Richard Williams is senior scientist and group leader at the Kennedy Institute of Rheumatology, University of Oxford, and carries out basic research about the enzyme IDO1 and rheumatoid arthritis. Kennedy Institute is a world famous institute in rheumatoid arthritis and research from there has led to the development of the main current drug treatment of rheumatoid arthritis. Richard Williams was recently appointed as an Editor of the scientific journal Arthritis Research & Therapy.